AR029479A1 - Derivados de flavonas, su procedimiento de preparacion, medicamento, composiciones farmaceuticas y utilizacion de dichos derivados para la preparacion de un medicamento - Google Patents
Derivados de flavonas, su procedimiento de preparacion, medicamento, composiciones farmaceuticas y utilizacion de dichos derivados para la preparacion de un medicamentoInfo
- Publication number
- AR029479A1 AR029479A1 ARP010100941A ARP010100941A AR029479A1 AR 029479 A1 AR029479 A1 AR 029479A1 AR P010100941 A ARP010100941 A AR P010100941A AR P010100941 A ARP010100941 A AR P010100941A AR 029479 A1 AR029479 A1 AR 029479A1
- Authority
- AR
- Argentina
- Prior art keywords
- alk
- radicals
- alkyl
- derivatives
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 2
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 2
- 239000011707 mineral Substances 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000003831 deregulation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229930003944 flavone Natural products 0.000 abstract 1
- 150000002212 flavone derivatives Chemical class 0.000 abstract 1
- 150000002213 flavones Chemical class 0.000 abstract 1
- 235000011949 flavones Nutrition 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000009223 neuronal apoptosis Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 150000007530 organic bases Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de flavonas, que comprenden la formula (1) en la cual: R1 representa un radical carbocíclico o heterocíclico, monocíclico o bicíclico, que incluye como máximo 12 eslabones, saturado o insaturado, que contiene uno o varios heteroátomos iguales o diferentes escogidos entre O, N, NH o S y que puede contener un eslabon -C(O), estando eventualmente sustituidos los radicales carbocíclico y heterocíclico tal como se definieron con anterioridad para R1 con uno o varios radicales escogidos entre átomos de halogenos; radicales hidroxilo; cicloalquilo que incluye como máximo 6 eslabones; acilo C1-7; ciano; nitro; carboxi libre, salificado o esterificado; tetrazolilo; -NH2, -NH(alk), -N(alk)alk; SO2-NH-CO-NHR5, en el que R5 representa un radical alquilo o fenilo; -C(O)-NH2, -C(O)-NH(alk), -C(O)-N(alk)alk, -NH-C(O)-(alk), -N(alk)-C(O)-(alk); tienilo; fenilo; alquilfenilo; alquilo; alquenilo; alquiltio; alcoxi o fenoxi, los cuales están eventualmente sustituidos con uno o varios radicales escogidos entre átomos de halogenos, radicales -NH2, -NH(alk), -N(alk)(alk) y radicales heterocíclicos, monocíclicos o bicíclicos, que están eventualmente sustituidos con uno o varios radicales escogidos entre radicales alquilo y átomos de halogenos; R2 y R3 son tales que uno representa un átomo de hidrogeno y el otro representa un radical piperidinilo eventualmente sustituido con uno o varios radicales hidroxilo y alquilo, pudiendo adoptar alternativamente R2 y R3 los mismos valores para proporcionar los isomeros correspondientes; R4 representa un átomo de hidrogeno, un radical alquilo o fenilo eventualmente sustituidos con uno o varios átomos de halogenos; debiendo entenderse que en los radicales anteriores, los radicales alquilo y alcoxi son lineales o ramificados e incluyen como máximo 6 átomos de carbono, estando dichos productos de formula (1) en todas las formas isomeras posibles racémicas, enantiomeras y diastereomeras, así como las sales por adicion de ácidos minerales y orgánicos o de bases minerales y orgánicas de dichos productos de formula (1). Un procedimiento para su preparacion, composiciones farmacéuticas y medicamentos que comprenden dichos derivados de flavonas y utilizacion de los mismos para la preparacion de medicamentos destinados a la prevencion o al tratamiento de enfermedades asociadas a una desregulacion de la secrecion y/o la actividad de proteínas tirosina quinasas y a la quimioterapia de cánceres, al tratamiento de la psoriasis, de parasitosis tales como las debidas a hongos o protistas, al tratamiento de la enfermedad de Alzheimer o al tratamiento de afecciones neurodegenerativas, particularmente apoptosis neuronal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0002528A FR2805538B1 (fr) | 2000-02-29 | 2000-02-29 | Nouveaux derives de flavones, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029479A1 true AR029479A1 (es) | 2003-07-02 |
Family
ID=8847520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100941A AR029479A1 (es) | 2000-02-29 | 2001-02-28 | Derivados de flavonas, su procedimiento de preparacion, medicamento, composiciones farmaceuticas y utilizacion de dichos derivados para la preparacion de un medicamento |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20030119816A1 (es) |
| EP (1) | EP1261603B1 (es) |
| JP (1) | JP5118282B2 (es) |
| AR (1) | AR029479A1 (es) |
| AT (1) | ATE336490T1 (es) |
| AU (1) | AU783663B2 (es) |
| CA (1) | CA2403424C (es) |
| CY (1) | CY1105786T1 (es) |
| DE (1) | DE60122295T2 (es) |
| DK (1) | DK1261603T5 (es) |
| ES (1) | ES2270984T3 (es) |
| FR (1) | FR2805538B1 (es) |
| MY (1) | MY159418A (es) |
| PT (1) | PT1261603E (es) |
| TW (1) | TWI282338B (es) |
| WO (1) | WO2001064673A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102812014B (zh) * | 2009-10-30 | 2016-01-20 | 多美恩医疗公司 | 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途 |
| CN103896895A (zh) * | 2013-12-31 | 2014-07-02 | 浙江工业大学 | 一种香豆素衍生物的制备方法 |
| ES2739749T3 (es) | 2015-05-18 | 2020-02-03 | Tolero Pharmaceuticals Inc | Profármacos de alvocidib que tienen biodisponibilidad aumentada |
| WO2018094275A1 (en) * | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| WO2020117988A1 (en) | 2018-12-04 | 2020-06-11 | Tolero Pharmaceuticals, Inc. | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
| CN111057035B (zh) * | 2019-11-05 | 2021-10-26 | 中国人民解放军第二军医大学 | 一种黄芩素衍生物及其制备方法与应用 |
| GB202104122D0 (en) * | 2021-03-24 | 2021-05-05 | Floratek Pharma Ag | Compounds and their use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN164232B (es) * | 1986-04-11 | 1989-02-04 | Hoechst India | |
| DE3836676A1 (de) * | 1988-10-28 | 1990-05-03 | Hoechst Ag | Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel |
| US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US5908934A (en) * | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
-
2000
- 2000-02-29 FR FR0002528A patent/FR2805538B1/fr not_active Expired - Fee Related
-
2001
- 2001-02-27 AU AU37501/01A patent/AU783663B2/en not_active Ceased
- 2001-02-27 EP EP01909906A patent/EP1261603B1/fr not_active Expired - Lifetime
- 2001-02-27 CA CA2403424A patent/CA2403424C/fr not_active Expired - Fee Related
- 2001-02-27 WO PCT/FR2001/000561 patent/WO2001064673A1/fr not_active Ceased
- 2001-02-27 ES ES01909906T patent/ES2270984T3/es not_active Expired - Lifetime
- 2001-02-27 DE DE60122295T patent/DE60122295T2/de not_active Expired - Lifetime
- 2001-02-27 TW TWNEWDERIVA patent/TWI282338B/zh not_active IP Right Cessation
- 2001-02-27 PT PT01909906T patent/PT1261603E/pt unknown
- 2001-02-27 JP JP2001563513A patent/JP5118282B2/ja not_active Expired - Fee Related
- 2001-02-27 AT AT01909906T patent/ATE336490T1/de active
- 2001-02-27 DK DK01909906T patent/DK1261603T5/da active
- 2001-02-27 US US10/181,677 patent/US20030119816A1/en not_active Abandoned
- 2001-02-27 MY MYPI20010863A patent/MY159418A/en unknown
- 2001-02-28 AR ARP010100941A patent/AR029479A1/es not_active Application Discontinuation
-
2006
- 2006-11-15 CY CY20061101663T patent/CY1105786T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5118282B2 (ja) | 2013-01-16 |
| DK1261603T5 (da) | 2007-07-09 |
| FR2805538A1 (fr) | 2001-08-31 |
| US20030119816A1 (en) | 2003-06-26 |
| DK1261603T3 (da) | 2006-12-27 |
| DE60122295T2 (de) | 2007-11-15 |
| CA2403424A1 (fr) | 2001-09-07 |
| CY1105786T1 (el) | 2011-02-02 |
| AU783663B2 (en) | 2005-11-24 |
| DE60122295D1 (de) | 2006-09-28 |
| PT1261603E (pt) | 2007-01-31 |
| JP2003525290A (ja) | 2003-08-26 |
| EP1261603A1 (fr) | 2002-12-04 |
| MY159418A (en) | 2017-01-13 |
| ES2270984T3 (es) | 2007-04-16 |
| ATE336490T1 (de) | 2006-09-15 |
| CA2403424C (fr) | 2011-02-01 |
| AU3750101A (en) | 2001-09-12 |
| TWI282338B (en) | 2007-06-11 |
| EP1261603B1 (fr) | 2006-08-16 |
| WO2001064673A1 (fr) | 2001-09-07 |
| FR2805538B1 (fr) | 2006-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
| ES2213732T3 (es) | Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos. | |
| GT200600159A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| SV2010003706A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas | |
| CR6565A (es) | Pirimidina-2,4,6-trionas inhibidores de metloproteinas | |
| SV2006002103A (es) | Compuestos de aril- o heteroarilamida ortosustituidos ref. pc32242a | |
| AR009357A1 (es) | Compuesto de amidas de acido fosfinico y sus usos para preparar una composicion farmaceutica y en un metodo para prevenir o tratar unaenfermedad asociada a la actividad de metaloproteasa | |
| UY27427A1 (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos | |
| BR0010555A (pt) | Inibidores de neuraminidases | |
| ES2136037B1 (es) | Inhibidores de sulfamida-metaloproteasa | |
| SV1995000074A (es) | Acidos 4-biarilbutirico o 5-biarilpentanoico sustituidos y sus derivados como inhibidores de las metaloproteasas de la matriz | |
| UY27360A1 (es) | Compuestos heterobicíclicos sustituídos con triamida | |
| AR063528A1 (es) | Peptidos inhibidores de la exocitosis neuronal | |
| UY27872A1 (es) | Inhibidores de caspasa y usos de los mismos. | |
| CR9507A (es) | Sulfonamidas de diarisulfona y sus usos | |
| AR074053A1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y composiciones farmaceuticas que los contienen | |
| AR029479A1 (es) | Derivados de flavonas, su procedimiento de preparacion, medicamento, composiciones farmaceuticas y utilizacion de dichos derivados para la preparacion de un medicamento | |
| FR2836917B1 (fr) | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif | |
| CO6311081A2 (es) | Derivados de piperidina 3,4 sustituida como inhibidores de renina | |
| MX9307232A (es) | Arilcicloalquilaminas n,n-disustituidas, sus sales, medicamentos que contiene estos compuestos y su empleo, asi como procedimientos para su preparacion. | |
| AR036187A1 (es) | Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario | |
| AR013462A1 (es) | Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos | |
| AR046874A1 (es) | Nuevos metodos | |
| CL2004000226A1 (es) | Compuestos derivados de [4-amino-2-((cicloalquilo, heterociclo)-amino)-pirimidin-5-il]-(arilo, heteroarilo, cicloalquilo o heterociclo)metanoma, inhibidores de quinasas ciclina-dependientes, en particular de (cdk4); proceso de preparacion; compuesto | |
| AR029461A1 (es) | Derivados de 4-fenil-1-piperazinilo, - piperidinilo y -tetrahidropiridilo , composiciones farmaceuticas que los comprenden y el uso de los mismos para la fabricacion de un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |